Clinical trials
Phase 2 Glomerulonephritis, IGA trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 8 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 7 |
| Completed | 6 |
| Not yet recruiting | 6 |
| Active, not recruiting | 3 |
| Terminated | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chengdu Suncadia Medicine Co., Ltd. | 2 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | 2 |
| Haisco Pharmaceutical Group Co., Ltd. | 2 |
| Keymed Biosciences Co.Ltd | 2 |
| Novartis Pharmaceuticals | 2 |
| ADARx Pharmaceuticals, Inc. | 1 |
| Air Force Military Medical University, China | 1 |
| Alexion Pharmaceuticals, Inc. | 1 |
| Biocity Biopharmaceutics Co., Ltd. | 1 |
| Everest Medicines (China) Co.,Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glomerulonephritis, IGA | 26 |
| Diabetic Nephropathies | 1 |
| Glomerulonephritis, Membranoproliferative | 1 |
| Glomerulosclerosis, Focal Segmental | 1 |
| Kidney Diseases | 1 |
| Lupus Nephritis | 1 |
| Necrosis | 1 |
| Nephrosis, Lipoid | 1 |
| Proteinuria | 1 |
| Renal Insufficiency, Chronic | 1 |
Trials
Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.